GlassScriptPhysician profile
Marc D Sullivan
NPI 1437350030
$5,527.03
in general payments reported to CMS, 2019-2025
42 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $628 · 2021: $1,164 · 2022: $524 · 2023: $461 · 2024: $947 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.28 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $692.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $480.03 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $452.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $396.30 | 2019-2020 | |
| Novo Nordisk INC | $386.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $343.17 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $228.73 | 2020-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.08 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $177.83 | 2020-2024 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $171.09 | 2019-2021 | |
| Lucid Diagnostics INC. | $126.60 | 2021 | |
| Pfizer INC. | $91.64 | 2019-2025 | |
| Amarin Pharma, INC. | $82.62 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $70.54 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.